All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides tailored viral vectors, including both retrovirus and lentivirus, for the precise modification of T cells. Engineered, customized vectors that deliver specific genes into T cells, enabling them to recognize and eliminate cancer cells. The production process follows strict current Good Manufacturing Practices (cGMP), ensuring the highest levels of safety, quality, and regulatory compliance. With scalable manufacturing, robust purification methods, and comprehensive quality control testing, custom cGMP virus production supports the unique needs of CAR-T therapy development, from early research through clinical trials and commercialization. This service ensures that the viral vectors produced are safe, potent, and ready for therapeutic use, accelerating the advancement of personalized cancer treatments.
Custom CGMP virus production for CAR-T therapy includes various types of viral vectors tailored for gene delivery in T cells. The primary types include:
Retroviral vectors are widely used to integrate the CAR gene into T cells. Retroviruses are particularly effective in gene therapy applications due to their ability to stably integrate genetic material into the host genome, ensuring long-term gene expression. cGMP retrovirus production focuses on producing high-titer, purified vectors that meet clinical-grade standards for CAR-T therapies.
You can click here to get more information!
Lentiviral vectors are another key option for CAR-T therapy, especially for their ability to transduce both dividing and non-dividing cells. Lentiviruses offer stable, long-term expression of the CAR gene and are favored for complex genetic modifications in T cells. cGMP lentivirus production ensures high-quality, safe vectors that are suitable for both research and clinical applications.
You can click here to get more information!
Adenovirus Production
While less common in CAR-T therapy, adenoviral vectors can be used for transient expression of the CAR gene. These vectors are non-integrating, meaning they do not modify the host genome permanently. cGMP adenovirus production focuses on providing high-quality vectors with controlled and transient gene expression, suitable for certain CAR-T applications or vaccine development.
AAV (Adeno-Associated Virus) Production
Though not typically used in CAR-T, AAV vectors are employed in gene therapy and can potentially play a role in delivering genetic material to modify T cells or in preconditioning patients' immune systems. cGMP AAV production services ensure high-purity and safe vectors for clinical use.
You can click here to get more information!
Custom cGMP Virus Production for CAR-T therapy offers several significant advantages, enhancing the development and clinical success of personalized cancer treatments:
Ready to explore how our Custom cGMP Virus Production services can accelerate your CAR-T therapy development? Contact Creative Biolabs today to discuss your specific project needs and learn how our tailored solutions can support your specific immunotherapy goals. Our experienced team is here to provide personalized guidance, answer any questions, and help you navigate the complexities of viral vector production. Reach out via phone, email, or by completing the contact form below, and we'll respond promptly to assist you in bringing your therapy to the next stage.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION